Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
COAG · Why this verdict
Why Hemab Therapeutics Holdings, In (COAG) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Hemab Therapeutics is a pre-revenue biotech with a 58.5% gap to the analyst target and institutional accumulation, but quality is below the floor, there is no revenue, and the outcome is binary on clinical results.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality scores 2.5, below the 4.0 floor, because the company reports zero revenue and gross, operating and net margin components all at 0.0. Quality | The company should show its first revenue or partnership income, and quality should rise toward the 4.0 floor. | →Stable |
| CounterA pre-revenue biotech is expected to score poorly on margins, so the low quality score reflects the business stage rather than deteriorating fundamentals. | ||
The $34.40 price sits 58.5% below the $54.52 analyst target, with analyst-implied upside of 82% before the engine's haircut. Analyst target | Price should close part of the gap to the $54.52 target over the next 12 months as clinical milestones are reached. | →Stable |
| CounterOnly 6 analysts cover the stock, so the signal is dampened, and biotech targets depend on trial outcomes that can fail and erase the premium. | ||
Institutions are accumulating shares, with the holder-change component at the maximum 10.0 and no net insider activity. Insider breakdown | Institutional ownership should keep rising, and insiders should stay neutral or become net buyers. | →Stable |
| CounterInstitutional buying in a small biotech is often ahead of a binary event, and large holders can reverse quickly if a trial disappoints. | ||
The stock is rated speculative because biotechnology outcomes are binary, and the stock sits at a 15.0% downside to the stop with volatility scoring 0.0 on risk. Suitability rationale | The stock should hold above its $31.99 stop level through upcoming clinical updates. | →Stable |
| CounterDebt-to-equity scores the maximum 10.0, so the balance sheet carries little leverage and can fund development without immediate dilution. | ||
Momentum scores 6.1 with rising on-balance volume and a strong MACD component of 10, indicating buyers are leading the move. Momentum breakdown | Momentum score should stay above 5.5 with volume accumulation continuing. | ↓Deteriorating |
| CounterTechnical scores are weak (2.1 overall, with price positioned low in its 52-week range), so momentum could fade quickly without a clinical catalyst. | ||
Quality scores 2.5, below the 4.0 floor, because the company reports zero revenue and gross, operating and net margin components all at 0.0.
→StableQuality
- Expectation
- The company should show its first revenue or partnership income, and quality should rise toward the 4.0 floor.
CounterA pre-revenue biotech is expected to score poorly on margins, so the low quality score reflects the business stage rather than deteriorating fundamentals.
The $34.40 price sits 58.5% below the $54.52 analyst target, with analyst-implied upside of 82% before the engine's haircut.
→StableAnalyst target
- Expectation
- Price should close part of the gap to the $54.52 target over the next 12 months as clinical milestones are reached.
CounterOnly 6 analysts cover the stock, so the signal is dampened, and biotech targets depend on trial outcomes that can fail and erase the premium.
Institutions are accumulating shares, with the holder-change component at the maximum 10.0 and no net insider activity.
→StableInsider breakdown
- Expectation
- Institutional ownership should keep rising, and insiders should stay neutral or become net buyers.
CounterInstitutional buying in a small biotech is often ahead of a binary event, and large holders can reverse quickly if a trial disappoints.
The stock is rated speculative because biotechnology outcomes are binary, and the stock sits at a 15.0% downside to the stop with volatility scoring 0.0 on risk.
→StableSuitability rationale
- Expectation
- The stock should hold above its $31.99 stop level through upcoming clinical updates.
CounterDebt-to-equity scores the maximum 10.0, so the balance sheet carries little leverage and can fund development without immediate dilution.
Momentum scores 6.1 with rising on-balance volume and a strong MACD component of 10, indicating buyers are leading the move.
↓DeterioratingMomentum breakdown
- Expectation
- Momentum score should stay above 5.5 with volume accumulation continuing.
CounterTechnical scores are weak (2.1 overall, with price positioned low in its 52-week range), so momentum could fade quickly without a clinical catalyst.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.9 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 0.0 |
- ▸Overbought bear rally (RSI 72)
- ▸Volume accumulation (rising OBV)
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 7.6 |
| Price target | 9.7 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 58%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
2.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.3 |
| 52w position | 4.3 |
| gap | 5.0 |
Risk (lower is worse)
5.1/10data confidence 60%| Component | Sub-score |
|---|---|
| days to cover | 5.3 |
| volatility | 0.0 |
| debt equity | 10.0 |
Catalyst
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 3.5 |
| news activity | 5.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:6.1>=5.5
- ASYMMETRY:2.5>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:17d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
2.49
Upside
+37.4%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.8B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 2.49.
The strongest dimensions are Value at 9.0, Sentiment at 7.9, and Insider at 7.3; the weakest are Technical at 2.4, Quality at 2.5, and Growth at 5.0. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 2.49 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analyst Target Upside
Trip ifAnalyst target falls below $37.80, leaving less than 10% upside from the current $34.40.
- P2Pre Revenue Quality Below Floor
Trip ifQuality score stays below 4.0 for 4 consecutive quarters with revenue still at 0.
- P3Institutions Accumulating
Trip ifInstitutional holder-change score falls below 5.0 from the current 10.0.
- P4Binary Clinical Risk Small Cap
Trip ifPrice falls below the $31.99 stop level, more than 7% under the current $34.40.
- P5Volume Accumulation Momentum
Trip ifMomentum score falls below 4.5 from the current 6.1.